Category - Developments

Developments

eGenesis and OrganOx report FDA clearance of IND application for ACLF treatment

Closely held eGenesis and OrganOx announced that the FDA has cleared the IND application for EGEN-5784—a human-compatible, genetically engineered porcine liver—designed for use in combination with the OrganOx...

April 15, 2025

Developments

Ironwood reports updates on apraglutide following FDA interaction

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced that a confirmatory Phase 3 trial evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and dependence on parenteral support, is a requirement...

April 14, 2025

Developments

Mayo study validates Aditxt’s ADI-100 induces immune tolerance to GAD

Aditxt (NASDAQ:ADTX) announced that a Mayo Clinic study has confirmed ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD)—a key autoantigen connected to multiple autoimmune conditions including Type 1...

April 14, 2025

Developments

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine. According to...

April 11, 2025

Developments

Chamath Palihapitiya Discusses Perimeter Medical’s AI-Driven Cancer Margin Imaging on Flagrant Podcast

During a recent episode of the Flagrant podcast hosted by Andrew Schulz and Akash Singh, investor and entrepreneur Chamath Palihapitiya offered a compelling example of how medical innovation can drive meaningful...

April 10, 2025

Developments

ARPA-H grants Ginkgo and partners $29M to advance distributed manufacturing of medicines using grain

Ginkgo Bioworks (NYSE:DNA) announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H) and partners—Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by...

April 10, 2025

Developments

FDA grants three FTDs for Allogene’s ALLO-329

Allogene Therapeutics (NASDAQ:ALLO) announced that the FDA has granted three fast track designations (FTDs) for its ALLO-329, a next-generation dual-target CD19/CD70 allogeneic CAR T for the treatment of lupus...

April 8, 2025

Developments

TrillaMed and Profound partner to bring TULSA-PRO to Veterans and service members

Profound Medical (NASDAQ:PROF; TSX:PRN) and TrillaMed, a Service-Disabled Veteran-Owned Business (SDVOSB), have announced a partnership to support the federal deployment of TULSA-PRO—the MRI-guided, incision-free...

April 4, 2025

Developments

AC Immune reveals positive Phase 2 data from trial in early PD

AC Immune (NASDAQ:ACIU) announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn trial evaluating ACI-7104.056—its anti-alpha-synuclein (a-syn) active immunotherapy candidate—for the...

April 3, 2025

Developments

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...

March 31, 2025

Category - Developments

Subscribe